Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $165 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Alnylam Pharmaceuticals (ALNY) and maintained a $165 price target.
February 20, 2024 | 5:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Alnylam Pharmaceuticals and maintained a $165 price target.
The reiteration of a Neutral rating and maintenance of the $165 price target by Cantor Fitzgerald suggests no significant short-term price movement is expected. The analyst's view appears unchanged, indicating stability in the stock's outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100